This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- AZD-1656
- DrugBank Accession Number
- DB14810
- Background
AZD-1656 is under investigation in clinical trial NCT00747175 (A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for AZD-1656 (DB14810)
- Weight
- Average: 478.509
Monoisotopic: 478.196467961 - Chemical Formula
- C24H26N6O5
- Synonyms
- Not Available
- External IDs
- AZD1656
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Ethers
- Direct Parent
- Diarylethers
- Alternative Parents
- Benzamides / Pyrazinecarboxamides / 2-heteroaryl carboxamides / Benzoyl derivatives / Phenol ethers / Phenoxy compounds / Alkyl aryl ethers / Imidolactams / Heteroaromatic compounds / Tertiary carboxylic acid amides show 7 more
- Substituents
- 2-heteroaryl carboxamide / Alkyl aryl ether / Aromatic heteromonocyclic compound / Azacycle / Azetidine / Benzamide / Benzenoid / Benzoic acid or derivatives / Benzoyl / Carboxamide group show 18 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 660M185X4D
- CAS number
- 919783-22-5
- InChI Key
- FJEJHJINOKKDCW-INIZCTEOSA-N
- InChI
- InChI=1S/C24H26N6O5/c1-15-10-27-21(12-25-15)29-23(31)17-7-18(34-16(2)14-33-3)9-19(8-17)35-22-13-26-20(11-28-22)24(32)30-5-4-6-30/h7-13,16H,4-6,14H2,1-3H3,(H,27,29,31)/t16-/m0/s1
- IUPAC Name
- 3-{[5-(azetidine-1-carbonyl)pyrazin-2-yl]oxy}-5-{[(2S)-1-methoxypropan-2-yl]oxy}-N-(5-methylpyrazin-2-yl)benzamide
- SMILES
- COC[C@H](C)OC1=CC(=CC(OC2=NC=C(N=C2)C(=O)N2CCC2)=C1)C(=O)NC1=NC=C(C)N=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 13168348
- ChEMBL
- CHEMBL3219124
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Active Not Recruiting Treatment End Stage Renal Disease (ESRD) / Kidney Transplantation / Transplanted Kidney Complication / Type 2 Diabetes Mellitus 1 2 Completed Treatment Coronavirus Disease 2019 (COVID‑19) 1 2 Completed Treatment Type 2 Diabetes Mellitus 4 1 Completed Not Available Glucose Lowering 1 1 Completed Not Available Type 2 Diabetes Mellitus 1 1 Completed Basic Science Hyperglycemia / Type 2 Diabetes Mellitus 1 1 Completed Basic Science Type 2 Diabetes Mellitus 1 1 Completed Treatment Healthy Subjects (HS) 2 1 Completed Treatment Type 1 Diabetes Mellitus 1 1 Completed Treatment Type 2 Diabetes Mellitus 13
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0443 mg/mL ALOGPS logP 1.92 ALOGPS logP 0.8 Chemaxon logS -4 ALOGPS pKa (Strongest Acidic) 13.09 Chemaxon pKa (Strongest Basic) 0.58 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 128.66 Å2 Chemaxon Rotatable Bond Count 9 Chemaxon Refractivity 127.74 m3·mol-1 Chemaxon Polarizability 50.25 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at May 20, 2019 14:28 / Updated at June 12, 2020 16:53